Description
Trancyp (Tranylcypromine) 10 mg
Trancyp 10 mg is a brand of tranylcypromine, an oral antidepressant in the monoamine oxidase inhibitor (MAOI) class. It is a prescription medicine used in selected cases of depressive disorder, particularly when other treatments have not been effective or have not been tolerated.
Active Ingredient and Medicine Class
The verified active ingredient is tranylcypromine. It is a nonselective, irreversible monoamine oxidase inhibitor, meaning it blocks enzymes that break down key neurotransmitters. This class has a long history in depression treatment but is used cautiously because of important food and drug interactions.
Established Medical Uses
Regulatory labeling identifies tranylcypromine as a treatment for major depressive disorder. Reviews of the clinical literature also describe its use in treatment-resistant depression and in some patients with atypical depressive features. It is generally reserved for cases where other antidepressant options have not worked well enough.
How It Works
Tranylcypromine inhibits monoamine oxidase, which helps increase the availability of neurotransmitters such as serotonin, norepinephrine and dopamine in the brain. This effect is thought to contribute to its antidepressant action. Because monoamine oxidase also helps break down tyramine and many medicines, inhibition can create clinically important interaction risks.
Important Safety Information
Tranylcypromine has major contraindications and interaction risks. It should not be combined with many serotonergic medicines or other MAO inhibitors because of the risk of serotonin syndrome. Tyramine-rich foods and certain drugs can trigger hypertensive crisis. U.S. prescribing information also warns against use with agents such as linezolid, intravenous methylene blue, and direct-acting sympathomimetics, and it lists multiple contraindicated or high-risk interacting medicines.
Because of these risks, tranylcypromine is not generally used as an initial antidepressant choice.
Possible Side Effects
Reported adverse effects include orthostatic hypotension, dizziness, headache, insomnia, restlessness and other blood-pressure-related effects. Serious reactions can include hypertensive crisis, serotonin syndrome and clinically significant cardiovascular or neuropsychiatric events.
Scientific Evidence
Peer-reviewed reviews and meta-analyses support antidepressant efficacy for tranylcypromine and other MAOIs in major depressive disorder, with particular relevance in treatment-resistant and atypical depression. However, these benefits must be weighed against the medicine’s interaction burden and tolerability limitations.
Medical Information Notice
This summary is educational and based on sources available at the time of review. It does not replace the official patient leaflet, prescribing information or individual assessment by a qualified healthcare professional.
Medical Sources
- DailyMed — TRANYLCYPROMINE tablet, prescribing information
- Nina Parikh, Musa Yilanli, Abdolreza Saadabadi — Tranylcypromine. StatPearls. 2025